Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
Arjun Puranik, View ORCID ProfilePatrick J. Lenehan, Eli Silvert, View ORCID ProfileMichiel J.M. Niesen, Juan Corchado-Garcia, View ORCID ProfileJohn C. O’Horo, View ORCID ProfileAbinash Virk, View ORCID ProfileMelanie D. Swift, View ORCID ProfileJohn Halamka, View ORCID ProfileAndrew D. Badley, View ORCID ProfileA.J. Venkatakrishnan, View ORCID ProfileVenky Soundararajan
doi: https://doi.org/10.1101/2021.08.06.21261707
Arjun Puranik
1nference, Cambridge, Massachusetts 02139, USA
Patrick J. Lenehan
1nference, Cambridge, Massachusetts 02139, USA
Eli Silvert
1nference, Cambridge, Massachusetts 02139, USA
Michiel J.M. Niesen
1nference, Cambridge, Massachusetts 02139, USA
Juan Corchado-Garcia
1nference, Cambridge, Massachusetts 02139, USA
John C. O’Horo
2Mayo Clinic, Rochester, Minnesota 55902, USA
Abinash Virk
2Mayo Clinic, Rochester, Minnesota 55902, USA
Melanie D. Swift
2Mayo Clinic, Rochester, Minnesota 55902, USA
John Halamka
2Mayo Clinic, Rochester, Minnesota 55902, USA
Andrew D. Badley
2Mayo Clinic, Rochester, Minnesota 55902, USA
A.J. Venkatakrishnan
1nference, Cambridge, Massachusetts 02139, USA
Venky Soundararajan
1nference, Cambridge, Massachusetts 02139, USA
Data Availability
After publication, the data will be made available upon reasonable requests to the corresponding author. A proposal with a detailed description of study objectives and the statistical analysis plan will be needed for evaluation of the reasonability of requests. Deidentified data will be provided after approval from the corresponding author and the Mayo Clinic.
Posted August 09, 2021.
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
Arjun Puranik, Patrick J. Lenehan, Eli Silvert, Michiel J.M. Niesen, Juan Corchado-Garcia, John C. O’Horo, Abinash Virk, Melanie D. Swift, John Halamka, Andrew D. Badley, A.J. Venkatakrishnan, Venky Soundararajan
medRxiv 2021.08.06.21261707; doi: https://doi.org/10.1101/2021.08.06.21261707
Comparison of two highly-effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence
Arjun Puranik, Patrick J. Lenehan, Eli Silvert, Michiel J.M. Niesen, Juan Corchado-Garcia, John C. O’Horo, Abinash Virk, Melanie D. Swift, John Halamka, Andrew D. Badley, A.J. Venkatakrishnan, Venky Soundararajan
medRxiv 2021.08.06.21261707; doi: https://doi.org/10.1101/2021.08.06.21261707
Subject Area
Subject Areas
- Addiction Medicine (399)
- Allergy and Immunology (709)
- Anesthesia (201)
- Cardiovascular Medicine (2944)
- Dermatology (249)
- Emergency Medicine (440)
- Epidemiology (12744)
- Forensic Medicine (12)
- Gastroenterology (828)
- Genetic and Genomic Medicine (4583)
- Geriatric Medicine (417)
- Health Economics (729)
- Health Informatics (2917)
- Health Policy (1069)
- Hematology (389)
- HIV/AIDS (924)
- Medical Education (426)
- Medical Ethics (115)
- Nephrology (469)
- Neurology (4354)
- Nursing (236)
- Nutrition (639)
- Oncology (2268)
- Ophthalmology (646)
- Orthopedics (258)
- Otolaryngology (325)
- Pain Medicine (279)
- Palliative Medicine (83)
- Pathology (501)
- Pediatrics (1196)
- Primary Care Research (496)
- Public and Global Health (6938)
- Radiology and Imaging (1527)
- Respiratory Medicine (915)
- Rheumatology (437)
- Sports Medicine (385)
- Surgery (489)
- Toxicology (60)
- Transplantation (212)
- Urology (181)